$JAGX
Jaguar Health, Inc.

2021 Q2 Form 10-Q Financial Statement

#000155837021011555 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q4
Revenue $385.0K $1.240M $2.580M
YoY Change -87.85% 42.53% 70.86%
Cost Of Revenue $664.0K $583.0K $790.0K
YoY Change -35.6% -14.26% 6.76%
Gross Profit -$279.0K $660.0K $1.790M
YoY Change -113.04% 247.37% 135.53%
Gross Profit Margin -72.47% 53.23% 69.38%
Selling, General & Admin $7.259M $5.548M $5.050M
YoY Change 32.32% 20.09% -2.7%
% of Gross Profit 840.61% 282.12%
Research & Development $3.870M $2.414M $1.900M
YoY Change 175.44% 52.78% 36.69%
% of Gross Profit 365.76% 106.15%
Depreciation & Amortization $431.0K $431.0K $430.0K
YoY Change 0.23% 0.23% -2.27%
% of Gross Profit 65.3% 24.02%
Operating Expenses $11.13M $7.962M $6.960M
YoY Change 61.5% 28.63% 5.78%
Operating Profit -$11.58M -$8.766M -$5.170M
YoY Change 37.03% 46.1% -11.17%
Interest Expense $2.009M $1.901M -$1.740M
YoY Change 319.42% -1050.5% 923.53%
% of Operating Profit
Other Income/Expense, Net -$17.00K $10.00K $0.00
YoY Change -121.79% -112.5% -100.0%
Pretax Income -$14.08M -$12.01M -$8.770M
YoY Change 52.42% 51.25% 47.15%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.08M -$12.01M -$8.770M
YoY Change 52.42% 51.25% 47.15%
Net Earnings / Revenue -3657.4% -968.47% -339.92%
Basic Earnings Per Share -$0.31 -$0.28
Diluted Earnings Per Share -$0.31 -$0.28 -$116.7K
COMMON SHARES
Basic Shares Outstanding 45.04M 42.64M
Diluted Shares Outstanding 45.04M 42.64M

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.99M $32.25M $8.090M
YoY Change 628.21% 2543.44% 131.14%
Cash & Equivalents $21.99M $32.25M $8.090M
Short-Term Investments
Other Short-Term Assets $14.73M $3.110M $2.360M
YoY Change 545.88% 69.95% 7.27%
Inventory $3.402M $2.820M $2.782M
Prepaid Expenses
Receivables $4.134M $5.900M $2.098M
Other Receivables $40.00K $30.00K $28.00K
Total Short-Term Assets $44.29M $44.10M $17.79M
YoY Change 281.52% 544.74% 86.89%
LONG-TERM ASSETS
Property, Plant & Equipment $666.0K $670.0K $677.0K
YoY Change -4.86% -5.63% -4.65%
Goodwill
YoY Change
Intangibles $23.49M $24.34M
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $20.00K $40.00K
YoY Change -100.0% -84.62% -73.33%
Total Long-Term Assets $25.25M $24.61M $25.05M
YoY Change -2.79% -6.92% -6.84%
TOTAL ASSETS
Total Short-Term Assets $44.29M $44.10M $17.79M
Total Long-Term Assets $25.25M $24.61M $25.05M
Total Assets $69.54M $68.71M $42.84M
YoY Change 85.04% 106.46% 17.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.918M $4.740M $4.759M
YoY Change -6.15% -15.36% -11.05%
Accrued Expenses $6.383M $6.410M $4.493M
YoY Change 28.43% 81.07% 37.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.145M $1.430M $3.790M
YoY Change -87.22% -79.94% -44.1%
Total Short-Term Liabilities $12.65M $12.59M $13.22M
YoY Change -48.9% -22.62% -14.1%
LONG-TERM LIABILITIES
Long-Term Debt $24.20M $24.23M $12.42M
YoY Change 5948.75% 5957.5% 2660.0%
Other Long-Term Liabilities $907.0K
YoY Change
Total Long-Term Liabilities $25.10M $24.23M $12.42M
YoY Change 6175.5% 5957.5% 2660.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.65M $12.59M $13.22M
Total Long-Term Liabilities $25.10M $24.23M $12.42M
Total Liabilities $37.75M $36.82M $25.64M
YoY Change 50.06% 120.88% 61.88%
SHAREHOLDERS EQUITY
Retained Earnings -$193.0M -$166.9M
YoY Change
Common Stock $224.8M $184.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.79M $31.89M $17.20M
YoY Change
Total Liabilities & Shareholders Equity $69.54M $68.71M $42.84M
YoY Change 85.04% 106.46% 17.67%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income -$14.08M -$12.01M -$8.770M
YoY Change 52.42% 51.25% 47.15%
Depreciation, Depletion And Amortization $431.0K $431.0K $430.0K
YoY Change 0.23% 0.23% -2.27%
Cash From Operating Activities -$9.905M -$6.708M -$4.060M
YoY Change 147.62% 56.0% 29.3%
INVESTING ACTIVITIES
Capital Expenditures -$6.000K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.000K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.573M 30.87M 10.80M
YoY Change 76.62% 1428.12% 118.18%
NET CHANGE
Cash From Operating Activities -9.905M -6.708M -4.060M
Cash From Investing Activities -6.000K 0.000 0.000
Cash From Financing Activities 9.573M 30.87M 10.80M
Net Change In Cash -338.0K 24.16M 6.740M
YoY Change -123.8% -1155.02% 272.38%
FREE CASH FLOW
Cash From Operating Activities -$9.905M -$6.708M -$4.060M
Capital Expenditures -$6.000K $0.00 $0.00
Free Cash Flow -$9.899M -$6.708M -$4.060M
YoY Change 147.47% 56.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Central Index Key
EntityCentralIndexKey
0001585608
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Revenue Practical Expedient Initial Application And Transition Nondisclosure Of Transaction Price Allocation To Remaining Performance Obligation
RevenuePracticalExpedientInitialApplicationAndTransitionNondisclosureOfTransactionPriceAllocationToRemainingPerformanceObligation
true
CY2018Q3 jagx Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2020Q2 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2021Q2 jagx Collaboration Revenue Net
CollaborationRevenueNet
0
CY2020Q3 jagx Collaboration Agreement Extension Term
CollaborationAgreementExtensionTerm
P2Y
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134436463
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23890931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129951263
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19516419
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36714
dei Entity Registrant Name
EntityRegistrantName
JAGUAR HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2956775
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Pine Street, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
371-8300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
JAGX
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21992000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8090000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9920000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4134000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2098000
CY2020Q4 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
2434000
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
40000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
28000
CY2021Q2 us-gaap Inventory Net
InventoryNet
3402000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4806000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
44294000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17792000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
666000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1085000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23494000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2020Q4 us-gaap Other Assets
OtherAssets
37000
CY2021Q2 us-gaap Assets
Assets
69539000
CY2020Q4 us-gaap Assets
Assets
42843000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4918000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4759000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6383000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4493000
CY2021Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7000
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
179000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1145000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3789000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12652000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13220000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907000
CY2021Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
6900000
CY2020Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
0
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
24195000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
12421000
CY2021Q2 us-gaap Liabilities
Liabilities
37754000
CY2020Q4 us-gaap Liabilities
Liabilities
25641000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
224760000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184090000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192989000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-166899000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
31785000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17202000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69539000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42843000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
664000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
1031000
us-gaap Cost Of Revenue
CostOfRevenue
1247000
us-gaap Cost Of Revenue
CostOfRevenue
1707000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3870000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1405000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6285000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2987000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2191000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1730000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4330000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3199000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5068000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3756000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8477000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6905000
CY2020Q2 jagx Warrants Inducement Expense
WarrantsInducementExpense
3696000
jagx Warrants Inducement Expense
WarrantsInducementExpense
1462000
jagx Warrants Inducement Expense
WarrantsInducementExpense
3696000
CY2021Q2 jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Convertible Preferred Stock Inducement Expense
ConvertiblePreferredStockInducementExpense
1647000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
11965000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
11618000
us-gaap Costs And Expenses
CostsAndExpenses
21973000
us-gaap Costs And Expenses
CostsAndExpenses
20141000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11580000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8451000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20348000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16105000
CY2021Q2 us-gaap Interest Expense
InterestExpense
2009000
CY2020Q2 us-gaap Interest Expense
InterestExpense
479000
us-gaap Interest Expense
InterestExpense
3909000
us-gaap Interest Expense
InterestExpense
678000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
CY2021Q2 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
475000
CY2020Q2 jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
386000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
1074000
jagx Fair Value Adjustment Of Warrants Conversion Option And Derivative Liability
FairValueAdjustmentOfWarrantsConversionOptionAndDerivativeLiability
387000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14081000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9238000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26090000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17174000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14081000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9238000
us-gaap Net Income Loss
NetIncomeLoss
-26090000
us-gaap Net Income Loss
NetIncomeLoss
-17174000
CY2021Q2 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-14081000
CY2020Q2 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-10597000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-26090000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-19013000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134436463
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23890931
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129951263
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19516419
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
31891000
CY2021Q2 jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1031000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-14081000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
31785000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6233000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
13000
CY2020Q2 jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
37000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
-503000
jagx Repayment Of Receivables Secured Borrowing
RepaymentOfReceivablesSecuredBorrowing
1822000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1500000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
146000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-76000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2300000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1909000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16615000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8298000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
309000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
749000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-9238000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1544000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17202000
jagx Stock Issued During Period Value Extinguishment Of Convertible Securities
StockIssuedDuringPeriodValueExtinguishmentOfConvertibleSecurities
2516000
jagx Stock Issued During Period In Exchange Of Notes Payable And Accrued Interest
StockIssuedDuringPeriodInExchangeOfNotesPayableAndAccruedInterest
2982000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1667000
us-gaap Profit Loss
ProfitLoss
-26090000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
31785000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10673000
jagx Stock Issued During Period Value Third Party For Services
StockIssuedDuringPeriodValueThirdPartyForServices
37000
us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
-983000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1509000
us-gaap Profit Loss
ProfitLoss
-17174000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1544000
us-gaap Profit Loss
ProfitLoss
-26090000
us-gaap Profit Loss
ProfitLoss
-17174000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2431000
us-gaap Share Based Compensation
ShareBasedCompensation
1667000
us-gaap Share Based Compensation
ShareBasedCompensation
1509000
jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
1462000
jagx Warrants Issued As Inducement To Exercise Equity Classified Warrants
WarrantsIssuedAsInducementToExerciseEquityClassifiedWarrants
3696000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-1074000
jagx Fair Value Adjustment Of Financial Instruments And Hybrid Instrument Designated At Fair Value Of Option
FairValueAdjustmentOfFinancialInstrumentsAndHybridInstrumentDesignatedAtFairValueOfOption
-387000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
861000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
863000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-753000
jagx Equity Line Of Credit Warrant Inducement Expense
EquityLineOfCreditWarrantInducementExpense
172000
jagx Derecognition Of Debt Discount
DerecognitionOfDebtDiscount
49000
jagx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1000
jagx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
365000
jagx Inducement Expense
InducementExpense
1647000
jagx Expense On Modification Of Warrants
ExpenseOnModificationOfWarrants
86000
jagx Common Stock And Warrants Issued
CommonStockAndWarrantsIssued
76000
jagx Common Stock Issued In Exchange Of Services Rendered
CommonStockIssuedInExchangeOfServicesRendered
37000
jagx Non Cash Consideration Paid Up On Acquisition Of Business Issuance Of Equity
NonCashConsiderationPaidUpOnAcquisitionOfBusinessIssuanceOfEquity
33000
jagx Loss On Recourse Obligation On Secured Borrowing
LossOnRecourseObligationOnSecuredBorrowing
-15000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-398000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2258000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
12000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
620000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
225000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1263000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
831000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-58000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
19000
jagx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-221000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10975000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
350000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
486000
jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
233000
jagx Repayment Of Insurance Premium Fee Classified As Financing Activity
RepaymentOfInsurancePremiumFeeClassifiedAsFinancingActivity
-776000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
50000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1515000
jagx Payment Of Equity Line Of Credit Warrant Offering Cost
PaymentOfEquityLineOfCreditWarrantOfferingCost
35000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
331000
jagx Proceeds From Sale Of Finance Receivable
ProceedsFromSaleOfFinanceReceivable
2222000
jagx Payments Of Warrant Issuance Costs
PaymentsOfWarrantIssuanceCosts
-185000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40443000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7437000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23822000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-868000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8090000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3883000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31912000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3015000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Interest Paid Net
InterestPaidNet
181000
jagx Shares Issued In Extinguishment Of Exchange Note
SharesIssuedInExtinguishmentOfExchangeNote
2982000
jagx Umbrella Insurance Financing
UmbrellaInsuranceFinancing
1183000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1087000
jagx Common Stock Issued Amount Upon Conversion Of Preferred Stock
CommonStockIssuedAmountUponConversionOfPreferredStock
476000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21992000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3015000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9920000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31912000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3015000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and the accompanying notes. The accounting policies that reflect the Company’s more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are the valuation of stock options, valuation of hybrid instruments designated at fair value option (“FVO”), valuation of warrant liabilities, acquired in-process research and development (“IPR&amp;D”), and useful lives assigned to long-lived assets; valuation adjustments for excess and obsolete inventory; allowance for doubtful accounts; deferred taxes and valuation allowances on deferred tax assets; evaluation and measurement of contingencies; and recognition of revenue, including estimates for product returns. Those estimates could change, and as a result, actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the World Health Organization declared the COVID-19 outbreak to be a pandemic. During the period ended June 30, 2021, the Company’s financial results were not significantly affected by the COVID-19 outbreak. The Company has considered all information available as of the date of issuance of these financial statements and the Company is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. The extent to which the COVID-19 outbreak affects the Company’s future financial results and operations will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak, and current or future domestic and international actions to contain and treat it.</p>
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
CY2021Q2 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
8000
CY2021Q2 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
6933000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
17000
CY2020Q2 jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
10000
jagx Depreciation Depletion And Amortization Of Property And Equipment
DepreciationDepletionAndAmortizationOfPropertyAndEquipment
20000
jagx Accounts Receivable Outstanding Period For Write Off
AccountsReceivableOutstandingPeriodForWriteOff
P2Y
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2020Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
jagx Number Of Contracts
NumberOfContracts
2
CY2021Q2 jagx Number Of Specialty Pharmacies
NumberOfSpecialtyPharmacies
2
jagx Number Of Portfolio Of Contract
NumberOfPortfolioOfContract
1
jagx Modifications To Liability Classified Instruments
ModificationsToLiabilityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Liability-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for debt modifications and exchange transactions, it is the Company’s policy to first determine whether it qualifies as a troubled debt restructuring (“TDR”) pursuant to the guidance provided in ASC 470-60. A debt modification or exchange transaction that is not within the scope of the ASC 470-60 is accounted for under ASC 470-50 to determine if the transaction is a mere modification or an extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company amended the terms of its October 2020 Purchase Agreement and Exchange Note 2 in the three and six months ended June 30, 2021, respectively (see Note 7). The Company did not modify any liability-classified instrument in the three and six months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p>
CY2021Q2 us-gaap Unusual Or Infrequent Item Insurance Proceeds
UnusualOrInfrequentItemInsuranceProceeds
0
jagx Modifications To Equity Classified Instruments
ModificationsToEquityClassifiedInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Modifications to Equity-classified Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for modifications of equity-classified warrants, it is the Company’s policy to determine the impact by analogy to the share-based compensation guidance of ASC 718, <i style="font-style:italic;">Compensation - Stock Compensation </i>(“ASC 718”). The model for a modified share-based payment award that is classified as equity and remains classified in equity after the modification is addressed in ASC 718-20-35-3. Pursuant to that guidance, the incremental fair value from the modification is recognized as an expense in the statements of operations to the extent the modified instrument has a higher fair value; however, in certain circumstances, such as when an entire class of warrants is modified, the measured increase in fair value may be more appropriately recorded as a deemed dividend, depending upon the nature of the warrant modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified certain equity-classified warrants in the three and six months ended June 30, 2020 (see Note 8). The Company did not modify any equity-classified warrants in the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accounting for amendments to preferred stock, it is the Company’s policy to measure the impact by analogy to ASC 470-50 in determining if such an amendment is an extinguishment or a modification. If the amendment results in an extinguishment, the Company follows the SEC staff guidance in ASC 260-10-S99-2 and ASC 470-20. If the amendment results in a modification, the Company follows the model in either ASC 718 or ASC 470-50, depending on the nature of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company modified the terms of its Series B convertible preferred stock in the six months ended <br/>June 30, 2020 (see Note 9). The Company did not modify any preferred stock in the three months ended June 30, 2020 and in the three and six months ended June 30, 2021.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassification of Prior Period Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Certain prior period amounts of cash flows from financing activities in the unaudited condensed consolidated statements of cash flows have been reclassified within the same category of cash flow activity to be consistent with the current period presentation. There were no reclassifications to other categories of cash flow activity and that the reclassification did not impact the profit or loss during the prior period.</p>
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
7000
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
6940000
CY2020Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
179000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
179000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6000000
CY2021Q2 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
933000
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
701000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1321000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1711000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1026000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
990000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
435000
CY2021Q2 us-gaap Inventory Net
InventoryNet
3402000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2782000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
948000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
942000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
282000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
265000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
666000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24337000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
422000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
843000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23494000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
843000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1687000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1687000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1687000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1687000
CY2021Q2 jagx Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
11103000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18694000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 jagx Letter Of Credit Received As Collateral
LetterOfCreditReceivedAsCollateral
475000
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
9580
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1085000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1106000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M1D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.2110
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
169000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
510000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
526000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
357000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1562000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
456000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1106000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907000
CY2020Q3 jagx Collaboration Agreement Term
CollaborationAgreementTerm
P2Y6M
CY2017Q3 jagx Percentage Of Amount Received To Be Paid To Glenmark
PercentageOfAmountReceivedToBePaidToGlenmark
0.25
CY2017Q3 jagx Maximum Amount To Be Received By Glenmark
MaximumAmountToBeReceivedByGlenmark
7000000.0
CY2017Q3 jagx Payments Made To Date To Glenmark
PaymentsMadeToDateToGlenmark
0
CY2018Q3 jagx Period To Amend Complaint From Date Of Dismissal
PeriodToAmendComplaintFromDateOfDismissal
P20D
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
2600000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
753000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7205454
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19421892
jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
506250
CY2020 jagx Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
22048278
jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-6021350
CY2020 jagx Class Of Warrant Or Right Exercises
ClassOfWarrantOrRightExercises
-34264393
CY2020 jagx Class Of Warrant Or Right Subject To Expire
ClassOfWarrantOrRightSubjectToExpire
323
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1690354
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7205454
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5100000
CY2019Q1 jagx Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
21
CY2019Q2 jagx Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
21
CY2019Q3 jagx Class Of Warrant Or Right Number Of Securities Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesExercisable
2781250
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4300000
CY2020Q1 jagx Class Of Warrant Or Right Number Of Securities Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesExercisable
208022
CY2020Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
653000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1021165
CY2019Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
500
CY2020Q4 jagx Carrying Amount In Excess Of Fair Value Amount New Instruments
CarryingAmountInExcessOfFairValueAmountNewInstruments
2500000
jagx Schedule Of Common Stock Reserved For Future Issuance
ScheduleOfCommonStockReservedForFutureIssuance
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:middle;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,924,063</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,456,748</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inducement options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,892</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options available for grant under stock option plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,486,818</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596,597</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock unit awards issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,613</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants issued and outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,690,354</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,205,454</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,559,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,379,304</p></td></tr></table>
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6924063
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4456748
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3486818
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
596597
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5613
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5613
CY2021Q2 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
1690354
CY2020Q4 jagx Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued And Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuedAndOutstandingNumber
7205454
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12559490
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12379304
jagx Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
10 years
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.45
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.58
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.31
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
895484
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
702364
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
1.57
jagx Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValueAmount
2.21
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1031000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
749000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1667000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1509000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021Q2 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-14081000
CY2020Q2 jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-10597000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-26090000
jagx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-19013000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
134436463
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23890931
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
129951263
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19516419
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9072672
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23360526
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-14081000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-9238000
us-gaap Profit Loss
ProfitLoss
-26090000
us-gaap Profit Loss
ProfitLoss
-17174000
CY2021Q2 us-gaap Investments
Investments
29241000
CY2020Q4 us-gaap Investments
Investments
29241000
CY2021Q2 jagx Loans Receivable Asset
LoansReceivableAsset
63075000
CY2020Q4 jagx Loans Receivable Asset
LoansReceivableAsset
41877000
CY2021Q2 us-gaap Assets
Assets
69539000
CY2020Q4 us-gaap Assets
Assets
42843000

Files In Submission

Name View Source Status
0001558370-21-011555-index-headers.html Edgar Link pending
0001558370-21-011555-index.html Edgar Link pending
0001558370-21-011555.txt Edgar Link pending
0001558370-21-011555-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jagx-20210630.xsd Edgar Link pending
jagx-20210630x10q.htm Edgar Link pending
jagx-20210630x10q_htm.xml Edgar Link completed
jagx-20210630xex31d1.htm Edgar Link pending
jagx-20210630xex31d2.htm Edgar Link pending
jagx-20210630xex32d1.htm Edgar Link pending
jagx-20210630xex32d2.htm Edgar Link pending
jagx-20210630_cal.xml Edgar Link unprocessable
jagx-20210630_def.xml Edgar Link unprocessable
jagx-20210630_lab.xml Edgar Link unprocessable
jagx-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending